Disruption in the diabetic device care market

Utkarsh Ojha¹
Raihan Mohammed²
¹Faculty of Medicine, Imperial College School of Medicine, Imperial College London, London, UK; ²Department of Medicine, University of Cambridge, Cambridge, UK

Abstract: As diabetes mellitus (DM) has approached pandemic proportions, the pressure for effective glycemic management is mounting. The starting point for managing and living well with DM involves early diagnosis and monitoring blood glucose levels. Therefore, self-monitoring of blood glucose (SMBG) can help patients maintain their blood glucose levels within the appropriate range. The general principle behind the current SMBG method involves a finger prick test to obtain a blood drop, which is applied onto a reagent strip and read by an automated device. Novel techniques are currently under evaluation to create the next generation of painless and accurate glucose monitoring for DM. We began by outlining how the emerging technology of the noninvasive glucose monitoring devices (NIGMDs) provides both economic and clinical benefits for health systems and patients. We further explored the engineering and techniques behind these upcoming devices. Finally, we evaluated how the NIGMDs disrupt the diabetic device care market and drive health care consumerism. We postulated that the NIGMDs play a pivotal role in the implementation of next generation of diabetes prevention strategies.

Keywords: medical devices, medical technology, diabetes management, innovation

Introduction

Diabetes mellitus (DM) is a metabolic disorder characterized by a chronic state of hyperglycemia. The global prevalence of DM has increased dramatically over the years. According to the 2014 World Health Organization (WHO) report, ~422 million adults have DM,¹ which will almost double by 2040.² As DM has approached pandemic proportions, the pressure for effective glycemic management is mounting. Both hypo- and hyperglycemia pose risks for patients with DM. Hypoglycemia is often associated with overuse of antidiabetic medications, which can result in convulsions, coma and even death. Hyperglycemia can also cause severe impairment to the heart, kidneys and brain. The starting point for managing and living well with DM involves early diagnosis and monitoring blood glucose levels. Therefore, self-monitoring of blood glucose (SMBG) can help patients maintain their blood glucose levels within the appropriate range. Blood glucose testing costs ~£175 million/year for the UK’s National Health Service (NHS).³ Guidance regarding the frequency of SMBG varies. It is generally recommended that patients taking insulin should frequently monitor their blood glucose levels. The American Diabetes Association advises patients using insulin to test their blood glucose levels three to four times per day.⁴ In the UK, >25 blood glucose meters are marketed to patients and health care professionals. The general principle behind the current SMBG method involves a finger prick test to obtain a blood drop, which is applied onto a reagent strip and read by an automated...
device. Novel techniques are currently under evaluation to create the next generation of painless and accurate glucose monitoring for DM.

**Limitations of the current SMBG technique**

Studies and guidelines highlight the importance of regular monitoring to maintain patients’ glycemic status as close to the normal range as safely as possible. However, each test strip and lancet can only be used once and thus bears a significant economic burden for both health systems and patients. Between 2013 and 2014, 581 million blood glucose tests were undertaken in the UK at a weighted average cost of £0.28. The current spending on blood glucose testing items per person in the Quality and Outcomes Framework (QoF) diabetes register is £60.88. Clinical commissioning groups are struggling to regulate these escalating SMBG costs, and SMBG is now a major contributor to NHS prescribing spending. For patients, the cost of test strips and needles has been associated with poor adherence to SMBG, increasing the risk of severe hypoglycemic episodes. Therefore, a noninvasive glucose monitoring device (NIGMD) has the potential to achieve significant efficiency savings for the NHS, without compromising care. A higher initial cost for the technology would be outweighed by greater cost savings using a reusable and more accurate device over a longer term.

Furthermore, current SMBG tests involve pricking the skin, typically on the finger, with the lancet. This process presents both a physical and mental barrier for diabetic patients. Pricking the fingertip four to ten times each day over several decades can cause scarring and loss of sensibility and perception. Burge reported that lanceting pain and finger soreness, alongside cost, are leading reasons for self-reported patient noncompliance with physician’s recommendations for SMBG. An NIGMD removes this physical and psychological barrier, improving patient compliance with respect to adequate glycemic control.

Finally, a major drawback of conventional SMBGs is the requirement to draw blood, thus increasing the risk of transmitting blood-borne infections. Over the past decade, diabetes prevalence has risen faster in low- and middle-income countries than in high-income countries. In these regions, conditions such as hepatitis and HIV predominate. Particularly, Africa has the highest WHO-estimated regional hepatitis C virus (HCV) prevalence of 5.3%. Although many of these cases occur due to transmission by nondiagnostic causes (e.g., mother to fetus), an NIGMD would reduce all risks associated with fingerstick glucometers. Infection transmission is not just restricted to developing countries; bacterial contamination of glucose test strips by highly pathogenic organisms including methicillin-resistant *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* have been reported in Spain. Since 1990, at least 147 people have acquired HBV infection over 18 outbreaks in USA, each attributed to glucose monitoring practices. Both studies highlight that outbreaks from current SMBG practices are currently underestimated due to underreporting and underrecognition of acute infections. An NIGMD eliminates risks of blood-borne infection transmission, allowing safer blood glucose measurement to improve patient safety.

**Emerging NIGMDs**

Most current noninvasive technologies are still in the early stages of development. Blood is the most obvious candidate for measuring glucose; however, other more accessible biological fluids, including interstitial fluid (ISF), ocular fluid, sweat and urine, are also under investigation as sample media. These techniques are outlined in Table 1 and are classed by the same regulatory approval as conventional blood glucose measuring devices.

In USA, a Class III in vitro device (IVD), which includes glucose monitors, requires premarket application, including a 180-day review with clinical data to assess safety (risk of misdiagnosis due to false positive or false negative) and to demonstrate effectiveness. However, the 21st Century Cures Act legislation seeks to boost the efficiency, predictability and transparency of MedTech approval processes and creates an expedited pathway for breakthrough medical technologies, such as an NIGMD. In Europe, there has been much debate that device regulation in the UK is insufficiently robust, with negligent approval processes putting patients at risk. Manufacturers can place a CE mark on their product to show that the medical device has met the requirements of their national competent authority, i.e., the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK. However, these independent notified bodies do not necessarily require clinical trial data of calibration, testing and inspection and has led to weak independent surveillance of technology. Thus, new EU regulations for IVDs entered into force in May 2017 with a 3- and 5-year transition period for the new risk classification criteria and greater safety and performance requirements.

Any NIGMD should be accurate and ideally be suitable for all age groups and patients. This is challenging as most technologies indirectly estimate glucose and suffer from interfering factors, due to the complexity of human body
of blood glucose level. Furthermore, developments in methods, and studies have shown that combining multiple technologies and sensors increase the signal-to-noise ratio of glucose to other contributors, giving an improved accuracy of blood glucose level. Furthermore, developments in composition and the natural variation of physiological processes. For example, transdermal approaches are affected by variations in skin characteristics (age, type and color) and patch replacements can also increase costs. Device calibration, especially for electrochemical techniques, can also be long and complex, varying from 30 minutes to 3 hours.

Thus, there has been a shift to the integration of multiple methods, and studies have shown that combining multiple technologies and sensors increase the signal-to-noise ratio of glucose to other contributors, giving an improved accuracy of blood glucose level. Furthermore, developments in continuous glucose monitoring, using analytic approaches and closed-loop control algorithms, have improved the accuracy of these devices to almost finger-stick levels. Similar applications of NIGMDs to incorporate analytic approaches may also close the accuracy gap and expedite regulatory approval. The accuracy of any NIGMD should fall within clinically accepted zones compared to a finger-stick glucometer, e.g., using Pearson coefficient, Clarke error grid or mean absolute relative difference. Unless a device meets this minimum threshold for all types of diabetes, it should not be approved for commercial use. One example of this is the

### Table 1: Current noninvasive glucose monitoring techniques

<table>
<thead>
<tr>
<th>Technique</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optical</td>
<td><strong>Infrared spectroscopy</strong></td>
<td>Low scattering, low-cost materials and good penetration</td>
</tr>
<tr>
<td></td>
<td><strong>Raman spectroscopy</strong></td>
<td>Sharper spectra and less sensitive to temperature changes</td>
</tr>
<tr>
<td></td>
<td><strong>Fluorescence</strong></td>
<td>Very sensitive. Little/no damage to the body</td>
</tr>
<tr>
<td>Surface plasmon resonance</td>
<td><strong>Fluorescence</strong></td>
<td>High signal:noise ratio, high resolution and good penetration</td>
</tr>
<tr>
<td>interferometry</td>
<td></td>
<td>Sensitive to individual's movement. Slightly affected by temperature</td>
</tr>
<tr>
<td>Optical coherence tomography</td>
<td></td>
<td>Sensitive to changes in temperature and pressure</td>
</tr>
<tr>
<td>Photoacoustic spectroscopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transdermal</td>
<td><strong>Impedance spectroscopy</strong></td>
<td>Differentiates between extracellular and intracellular fluids</td>
</tr>
<tr>
<td>Reverse iontophoresis</td>
<td></td>
<td>Requires 60 min of equilibration process</td>
</tr>
<tr>
<td>Electrochemical</td>
<td><strong>Enzymatic detection of glucose</strong></td>
<td>Specific frequencies can differentiate between glucose and glucose-containing compounds</td>
</tr>
<tr>
<td></td>
<td><strong>Amperometry</strong></td>
<td>Well commercial. Multiple sensors increase accuracy</td>
</tr>
<tr>
<td>Others</td>
<td><strong>Refractive changes in the eye</strong></td>
<td>Low sensitivity to scattering, so high signal:noise ratio</td>
</tr>
<tr>
<td></td>
<td><strong>Ultrasonic, electromagnetic and heat capacity</strong></td>
<td>Sensitive to interference from other compounds and temperature and pressure</td>
</tr>
</tbody>
</table>

Disruption in the diabetic device care market
“GlucoWatch”, which was the first NIGMD. Measurement was based on reverse iontophoresis of ISF through the skin. Although initially approved by the US Food and Drug Administration (FDA), it was later withdrawn from the market due to low accuracy, skin irritation and procedural problems.

As device accuracy remains elusive, currently, there is only one NIGMD that is available to the public; Abbott’s FreeStyle Libre was granted FDA approval in September 2016. It uses sensors to measure glucose in the ISF using an electrochemical technique, which is one of three general categories of current NIGMD technologies (Table 1). The sensor costs $57.95 and lasts up to 14 days of continuous use, leading to costs of just over £1,500 per patient per year. However, two key devices are planned to enter the market in 2017/2018, and we estimate that the resulting competition will drive down prices.

SugarBEAT uses a transdermal and electromagnetic technique to draw glucose from the ISF onto an adhesive skin patch. It is marketed as being suitable for people with Type I diabetes, Type II diabetes and prediabetes, has recently received a CE approval and is anticipated to be launched in early 2018 in the UK. GlucoTrack measures glucose levels using three different technologies: ultrasonic, electromagnetic and thermal sensors. Each measurement is then combined via a proprietary algorithm to calculate the weighted average of the patient’s glucose level. The device has received a CE approval and is intended for people with prediabetes and Type II diabetes but is not yet marketed in the EU/UK.

Other products are currently in clinical trials and are expected to come to market in the next 3–5 years. GlucoWise uses high-frequency (65 GHz) radio waves and nanocomposite films on the sensor to penetrate through tissues. NovioSense is a spring-like coil inserted under the lower eyelid that uses enzymatic action to detect glucose levels in tears. Finally, iQuickit and Glucose Pop Test devices use enzymatic action to detect glucose in saliva; however, there are concerns about how well the glucose levels in saliva and tears correlate with capillary blood glucose. We also have reservations about how keen potential users will be on a subconjunctival implant, especially with regard to children.

Recently, large tech companies, including Google and Apple, have entered this market with a view to revolutionize NIGMDs. The Google X lab and Novartis have collaborated on smart contact lenses, and Microsoft has designed sensory electrodes that could detect glucose when incorporated into flexible hydrogels. Thus, there is a significant market potential for NIGMDs and the technology is beginning to catch up.

**Disruptive innovation**

In 2016, the global diabetic care device market was valued at $19.05 billion. This valuation is estimated to reach $27.42 billion by 2022. The increasing prevalence of DM is the key driver for this trend, fueling the growth of the global SMBG device market at a compound annual growth rate (CAGR) of 12% (Figure 1). Bower and Christensen described “disruptive technologies” as entities that revolutionize an existing saturated business, much like the current SMBG market. The NIGMDs create a new market and value network that could not only disrupt but also replace current test strips. Furthermore, in some emerging markets including China and India, governmental support for health care and insurance is increasing and becoming more widespread. In these countries, the diabetic population is among the highest in the world; consequently, spending on diabetes treatment constitutes a large proportion of total medical expenditure.

These long-term macro fundamentals will therefore continue to fuel demand in the health care market, providing favorable economic conditions for developing technological innovations, such as the NIGMDs.

Larger companies generally work with sustaining technologies, which rely on incremental improvements to previously established products. Disruptive innovations require large capital investment and divert scarce resources for improving the accuracy and reliability of current products against current competition. This is especially true in the SMBG business environment of tight profit margins and declining test strip prices. As a result, larger firms rarely capitalize on the potential efficiencies, synergies or new marketing provided by disruptive technologies. Consequently, smaller biotech firms are given an opportunity to compete with larger companies and enter a competitive market through product differentiation.

Currently, just four companies – Roche Diagnostics, LifeScan, Bayer Healthcare Division and Abbott Laboratories – control 90% of the global diabetic care device market. Although these market leaders are dissuaded from pursuing disruptive innovations for the aforementioned reason, they may seek to acquire emerging technologies through mergers and acquisitions (M&A) to drive efficacy in health care. Indeed, the current economic conditions favor health care M&A activity, which has grown at a 50% CAGR from 2012 to 2015, over twice as fast as overall M&A activity. This pattern is largely attributed to historically low interest rates, which is being used strategically for debt financing. This increase in corporate leverage is driving financial engineering (i.e., buy-
Conventional use of cash by companies, such as paying debt and dividends can be regarded as “doing nothing” by company shareholders. Therefore, in order to maintain shareholders’ interest, company boards may be more inclined to exploit low interest to fund inorganic expansion. Hence, global MedTech M&A activity will continue at pace and intensify competition between large health care corporations to acquire disruptive technologies.

**Perspectives and concluding remarks**

In order to reduce the financial burden on health systems, policy makers are now focusing their attention on implementing effective prevention programs. The use of mobile phone messaging has shown great promise in delivering personalized advice and tackling diabetes prevention. In a randomized control trial by Ramachandran et al., men with impaired glucose tolerance were assigned into either a control arm, receiving standard diabetic care advice, or an interventional arm, receiving personalized advice via mobile phone messaging. The group reported that the cumulative incidence of Type II DM was lower in those receiving mobile phone messages. Although the study is limited to Indian males, the authors provide compelling insight into how technology can shape more successful avenues for preventing diabetes. New technologies are being developed that couple blood glucose monitoring devices to mobile phone applications and send blood glucose levels to patients’ mobile phones, allowing them to keep track of their progress. Each patient therefore receives recommendations about managing their diabetes, which is tailored to their needs. Bibbings et al. tested the accuracy of an NIGMD based on a smartphone application that uses artificial neural network to detect blood glucose levels. The authors showed that this technique is capable of accurately measuring both low and high blood glucose levels. Recently, a new blood glucose monitoring meter, the Contour®Next One, has been engineered, which can be linked via Bluetooth connectivity to smartphones. Christiansen et al. reported that this new device shows analytical and clinical accuracy and is easy to use in clinical settings among patients who have never used blood glucose monitoring devices previously.

The availability of a device for rapid assessment of blood glucose levels without skin puncture will not only revolutionize glucose monitoring at home and hospitals but also significantly disrupt the SMBG market space. In the UK, an NIGMD would achieve the greatest benefit per pound spent by NHS and reduce escalating SMBG costs. Clinically, patient compliance would increase alongside eliminating the risk of blood-borne infection transmission. It is conceivable that an NIGMD will play a pivotal role in the implementation of next generation of prevention strategies.

**Author contributions**

UO and RM were involved in the conception, design, drafting, revising and final approval of the article.
Disclosure

The authors report no conflicts of interest in this work.

References


